Your browser is no longer supported. Please, upgrade your browser.
Settings
VVUS VIVUS Inc. daily Stock Chart
VVUS [NASD]
VIVUS Inc.
Index- P/E- EPS (ttm)-0.87 Insider Own0.20% Shs Outstand103.19M Perf Week-5.17%
Market Cap113.51M Forward P/E- EPS next Y-0.45 Insider Trans282.30% Shs Float98.34M Perf Month-12.00%
Income-90.30M PEG- EPS next Q-0.10 Inst Own44.70% Short Float13.91% Perf Quarter-2.65%
Sales78.60M P/S1.44 EPS this Y-12.10% Inst Trans-11.26% Short Ratio16.35 Perf Half Y7.84%
Book/sh-0.18 P/B- EPS next Y6.20% ROA-31.70% Target Price7.27 Perf Year-55.82%
Cash/sh2.21 P/C0.50 EPS next 5Y0.80% ROE- 52W Range0.92 - 2.61 Perf YTD7.84%
Dividend- P/FCF- EPS past 5Y0.80% ROI-26.90% 52W High-57.85% Beta1.15
Dividend %- Quick Ratio4.80 Sales past 5Y- Gross Margin64.40% 52W Low20.22% ATR0.07
Employees82 Current Ratio5.00 Sales Q/Q-52.50% Oper. Margin-73.90% RSI (14)25.73 Volatility6.18% 5.84%
OptionableYes Debt/Eq- EPS Q/Q18.00% Profit Margin- Rel Volume13.15 Prev Close1.10
ShortableYes LT Debt/Eq- EarningsMay 03 AMC Payout- Avg Volume836.64K Price1.10
Recom3.00 SMA20-8.60% SMA50-18.89% SMA200-15.58% Volume11,004,837 Change0.00%
May-04-16Downgrade WallachBeth Buy → Hold
Nov-05-15Upgrade WallachBeth Hold → Buy $2.30 → $2.80
Jul-31-15Reiterated RBC Capital Mkts Outperform $6 → $4
Jan-23-15Initiated RBC Capital Mkts Outperform $6
Feb-25-14Reiterated WallachBeth Hold $11 → $8
Nov-15-13Initiated WallachBeth Hold $11
Oct-03-13Upgrade Cowen Hold → Outperform $19
Jul-19-13Downgrade Needham Buy → Hold
Jan-18-13Reiterated MLV & Co Buy $40 → $21
Sep-24-12Reiterated Needham Buy $38 → $32
Jul-19-12Reiterated MLV & Co Buy $34 → $40
Jul-18-12Reiterated Rodman & Renshaw Mkt Outperform $39 → $52
Jul-18-12Downgrade Brean Murray Buy → Hold
Apr-30-12Reiterated MLV & Co Buy $30 → $34
Feb-23-12Upgrade Rodman & Renshaw Mkt Perform → Mkt Outperform $39
Feb-23-12Upgrade Brean Murray Sell → Hold $2
Feb-23-12Reiterated MLV & Co Buy $22 → $30
Feb-23-12Reiterated JMP Securities Mkt Outperform $16 → $45
Jan-17-12Reiterated MLV & Co Buy $16 → $22
Jan-05-12Initiated Rodman & Renshaw Mkt Perform
Jun-21-16 04:07PM  VIVUS INC Files SEC form 8-K, Other Events
Jun-17-16 05:37PM  ETFs with exposure to VIVUS, Inc. : June 17, 2016
Jun-09-16 08:58AM  Orexigen Stock Gains More than 50% on Markman Hearing
Jun-03-16 03:48PM  ETFs with exposure to VIVUS, Inc. : June 3, 2016
May-23-16 09:01AM  Im traveling this week, so Im not able to write a new blog post, but I thought I would share the video of the presentation J. Carlo Cannell and I made at last years Stansberry Conference in Las Vegas. Im scheduled to present at the conf
May-18-16 11:01PM  ETFs with exposure to VIVUS, Inc. : May 19, 2016
May-17-16 04:31PM  VIVUS, Inc. :VVUS-US: Earnings Analysis: Q1, 2016 By the Numbers
11:31AM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Breaches of Fiduciary Duty by the Board of VIVUS Inc. - VVUS PR Newswire
May-16-16 12:53PM  Shareholder Alert: Purcell Julie & Lefkowitz LLP Is Investigating VIVUS, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors PR Newswire
May-10-16 01:04PM  VIVUS INC Financials
May-06-16 04:12PM  VIVUS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
May-05-16 04:14PM  VIVUS INC Files SEC form 8-K, Change in Directors or Principal Officers
May-04-16 10:28AM  Vivus downgraded by WallachBeth -8.67%
08:09AM  VIVUS (VVUS) Q1 Loss Narrower but Qsymia Sales Decline
08:07AM  Arena (ARNA) Q1 Earnings: What's in Store for the Stock?
May-03-16 09:34PM  Edited Transcript of VVUS earnings conference call or presentation 3-May-16 8:30pm GMT -5.06%
04:37PM  Vivus reports 1Q loss AP
04:15PM  VIVUS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
04:05PM  Vivus Reports 2016 First Quarter Financial Results Marketwired
04:05PM  VIVUS INC Files SEC form 10-Q, Quarterly Report EDGAR Online
07:07AM  Q1 2016 VIVUS Inc Earnings Release - After Market Close CCBN
Apr-19-16 06:00PM  VIVUS Announces Date of 2016 First Quarter Business Update and Financial Results Teleconference Marketwired
Apr-11-16 11:40AM  VIVUS (VVUS) Upgraded to Hold on Strong Fundamentals
Apr-07-16 09:30AM  Biotech Volatility Both Good And Bad Accesswire
Apr-04-16 03:45PM  ETFs with exposure to VIVUS, Inc. : April 4, 2016 +6.71%
08:05AM  VIVUS (VVUS) in Focus: Stock Jumps 6.4% in Session
Mar-25-16 10:06AM  ETFs with exposure to VIVUS, Inc. : March 25, 2016
Mar-14-16 04:12PM  VIVUS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits +6.78%
04:07PM  ETFs with exposure to VIVUS, Inc. : March 14, 2016
10:58AM  VIVUS, Inc. :VVUS-US: Earnings Analysis: Q4, 2015 By the Numbers
Mar-10-16 09:10AM  VIVUS Posts Narrower Loss in Q4 but Misses on Revenues
Mar-09-16 08:17PM  Edited Transcript of VVUS earnings conference call or presentation 9-Mar-16 9:30pm GMT
04:43PM  Vivus reports 4Q loss
04:23PM  VIVUS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:16PM  VIVUS INC Files SEC form 10-K, Annual Report
04:15PM  VIVUS Reports Fourth Quarter and Year-End 2015 Financial Results Marketwired
07:07AM  Q4 2015 VIVUS Inc Earnings Release - After Market Close
Feb-29-16 08:30AM  VIVUS Announces Date of Fourth Quarter 2015 Update and Financial Results Teleconference Marketwired
Jan-28-16 04:47PM  VIVUS INC Files SEC form 8-K, Change in Directors or Principal Officers
Jan-07-16 09:30AM  The Zacks Analyst Blog Highlights: Gilead, MannKind, VIVUS and Baxalta
Jan-06-16 02:50PM  Biotech Stock Roundup: MannKind Tanks on Deal Termination, Speedy Review for Gilead Drug
Jan-04-16 02:40PM  VIVUS to Regain U.S. and Canada Stendra Rights from Endo
Dec-31-15 04:15PM  VIVUS INC Files SEC form 8-K, Termination of a Material Definitive Agreement, Regulation FD Disclosure, Financial Sta
01:00PM  VIVUS, Inc. Announces Intent to Reacquire U.S. and Canadian Rights for Stendra(R) (Avanafil) Marketwired
Dec-29-15 09:00AM  A New Take On New Year's And Chronic Weight Management: Smart Changes Program Combines Positive Lifestyle Changes With Prescription Medication For Weight Loss PR Newswire
Dec-23-15 12:43PM  VIVUS, Inc. Earnings Analysis: Q3, 2015 By the Numbers
Dec-04-15 04:57PM  Orexigen Therapeutics, Inc.'s Stock Loses Weight on Downgrade at Motley Fool -7.14%
Dec-02-15 03:20PM  Zafgen Plunges On Death In Obesity-Drug Trial at Investor's Business Daily -6.25%
Nov-30-15 03:00PM  Should You Buy VIVUS, Inc. (VVUS)? at Insider Monkey -9.42%
Nov-29-15 11:17AM  Should You Buy Bravo Brio Restaurant Group, Inc. (BBRG)? at Insider Monkey
Nov-25-15 05:35PM  Drugmakers drop weight
Nov-24-15 04:12PM  VIVUS INC Files SEC form 8-K, Change in Directors or Principal Officers
Nov-23-15 08:20AM  Trading Ahead of Upcoming Developments - Research on Vivus, ReneSola, Consumer Portfolio Services and BioScrip Accesswire +5.69%
Nov-21-15 03:17PM  Do Hedge Funds Love Hurco Companies, Inc. (HURC)? at Insider Monkey
Nov-09-15 04:09PM  VIVUS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
Nov-05-15 04:16PM  VIVUS' (VVUS) Q3 Loss Grows Y/Y, Revenues Top Estimates
Nov-04-15 08:13PM  Edited Transcript of VVUS earnings conference call or presentation 4-Nov-15 9:30pm GMT
06:14PM  Vivus reports 3Q loss
04:30PM  VIVUS Inc Earnings Call scheduled for 4:30 pm ET today
04:18PM  VIVUS INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vote of Security
04:05PM  VIVUS Reports Third Quarter 2015 Financial Results Marketwired
07:07AM  Q3 2015 VIVUS Inc Earnings Release - After Market Close
Nov-03-15 07:00AM  VIVUS Announces Qsymia Presentations at Obesity Week 2015 Marketwired
Oct-28-15 07:00AM  VIVUS Announces Date of Third Quarter 2015 Update and Financial Results Teleconference GlobeNewswire -5.59%
Oct-20-15 04:07PM  VIVUS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits
Oct-05-15 04:07PM  VIVUS INC Files SEC form 8-K, Change in Directors or Principal Officers
Oct-01-15 01:25PM  3 Stocks Under $10 to Trade for Breakouts at TheStreet
09:25AM  BioMarin (BMRN) Looks Good: Stock Adds 8.8% in Session
Sep-29-15 08:44AM  VIVUS (VVUS) Catches Eye: Stock Shoots Up 9.6%
Sep-22-15 04:22PM  VIVUS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits +5.06%
04:05PM  VIVUS, Inc. Board of Directors Expresses No Opinion and Remains Neutral Toward Icahn Group's Unsolicited Offer to Purchase 4.50% Convertible Senior Notes Marketwired
Sep-18-15 09:21PM  Why Hasn't Orexigen Launched Its Obesity Drug in Europe Yet? at Motley Fool
04:08PM  VIVUS INC Files SEC form 8-K, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Ch
Sep-16-15 09:30AM  The Zacks Analyst Blog Highlights: VIVUS, Regeneron Pharmaceuticals, Gilead Sciences, Repligen and Affymetrix
Sep-15-15 11:36AM  Biotech Poised to Rebound: 5 Growth Picks
07:34AM  Can the Rally in VIVUS (VVUS) Shares Continue?
Sep-12-15 09:25AM  This Past Weeks Top 5 Biotech Movers at 24/7 Wall St.
Sep-10-15 08:40AM  Icahn Offer Considered - Critical Information for Vivus Shareholders Accesswire +14.81%
08:37AM  VIVUS (VVUS) in Focus: Stock Moves 12.5% Higher in Session
Sep-09-15 04:03PM  VIVUS, Inc. (VVUS) Tender Offer A Win-Win Deal For Carl Icahn at Insider Monkey +12.50%
Sep-03-15 12:08PM  5 Stocks Under $10 Set to Soar at TheStreet
Sep-01-15 02:49PM  4 Biotech Stocks Under $10 to Trade for Breakouts at TheStreet
Aug-31-15 08:40AM  Why VIVUS (VVUS) Could Shock the Market Soon
Aug-23-15 10:57AM  The 3 Most Disappointing Drug Launches of All Time at Motley Fool
Aug-18-15 04:07PM  VIVUS INC Files SEC form 8-K, Change in Directors or Principal Officers
Aug-14-15 05:04PM  Stocks Trading Near Their 52-Week Lows: 4 Hot Picks
Aug-13-15 09:18AM  VIVUS Inc. (VVUS) in Focus: Stock Jumps 5.4%
07:30AM  VIVUS (VVUS) Is in Oversold Territory: What's Next?
Aug-06-15 09:30AM  The Zacks Analyst Blog Highlights: Amgen, Vertex, Regeneron, Baxalta and VIVUS - Press Releases -10.00%
06:04AM  VIVUS INC Files SEC form 8-K, Change in Directors or Principal Officers, Other Events
Aug-05-15 08:09PM  10-Q for VIVUS, Inc. at Company Spotlight
04:49PM  VIVUS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
10:44AM  Biotech Stock Roundup: Baxalta Rejects Shire Bid, Amgen's Beat & Raise Quarter - Analyst Blog
Aug-04-15 01:00PM  Will Arena Pharmaceuticals (ARNA) Surprise Q2 Earnings? - Analyst Blog -9.72%
Aug-03-15 06:16AM  VIVUS INC Files SEC form 10-Q, Quarterly Report
Jul-31-15 05:55PM  Bay Area obesity drug maker slims down as market slows at bizjournals.com -12.72%
04:24PM  Express Scripts excludes 20 more drugs from 2016 coverage
03:52PM  Edited Transcript of VVUS earnings conference call or presentation 30-Jul-15 8:30pm GMT
03:25PM  Vivus (VVUS) Stock Falls Following Earnings Release, Restructuring Plan at TheStreet
11:06AM  VIVUS (VVUS) Q2 Loss Narrower, Restructuring Announced - Analyst Blog
VIVUS, Inc., a biopharmaceutical company, develops and commercializes therapies to address unmet medical needs in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of 30 or greater, or 27 or greater in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus or high cholesterol; and STENDRA, an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction. It is also developing Qsymia, which has completed Phase II studies for the treatment of obstructive sleep apnea and diabetes, as well as for other obesity-related diseases, including nonalcoholic steatohepatitis, nonalcoholic fatty liver disease, hyperlipidemia, and hypertension. The company has development, license and clinical trial, and commercial supply agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of avanafil, a PDE5 inhibitor compound for the oral and local treatment of male and female sexual dysfunction. It also has license and commercialization agreements with Berlin-Chemie AG and Auxilium Pharmaceuticals, Inc. to commercialize and promote SPEDRA; and with Sanofi Winthrop Industrie to commercialize and promote avanafil. VIVUS, Inc. was founded in 1991 and is headquartered in Mountain View, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Varghese Santosh TChief Medical OfficerApr 07Sale1.65329543101,891Apr 11 09:33 PM
NORTH TIDE CAPITAL, LLC10% OwnerApr 01Buy1.402,1603,02813,587,460Apr 05 04:08 PM
NORTH TIDE CAPITAL, LLC10% OwnerMar 31Buy1.36172,300234,22513,585,300Mar 31 05:15 PM
NORTH TIDE CAPITAL, LLC10% OwnerMar 30Buy1.25100,000125,45013,413,000Mar 31 05:15 PM
NORTH TIDE CAPITAL, LLC10% OwnerMar 29Buy1.21111,000133,84313,313,000Mar 31 05:15 PM
NORTH TIDE CAPITAL, LLC10% OwnerMar 28Buy1.13177,000199,39013,202,000Mar 28 04:46 PM
NORTH TIDE CAPITAL, LLC10% OwnerMar 24Buy1.0925,00027,24213,025,000Mar 28 04:46 PM
Varghese Santosh TChief Medical OfficerJan 13Sale0.951,5531,475102,220Apr 11 09:31 PM
Varghese Santosh TVP, Medical & Reg AffairsJul 01Sale2.327,89918,32641,234Jul 06 05:54 PM
Slebir John LSVP, Business Development & GCJul 01Sale2.329,21521,37963,584Jul 06 05:51 PM
Day WesleyVP, Clinical DevelopmentJul 01Sale2.327,88118,28449,118Jul 06 05:48 PM